Abstract 【Objective】To investigate the differential expression of homologous heterojunction box protein 2B (PHOX2B) in four subtypes of peripheral neuroblastoma (pNTs) tissues. 【Methods】A retrospective analysis was conducted on 65 children with pNTs admitted to our hospital from January 2019 to December 2022. The expression of PHOX2B in four subtypes of pNTs was analyzed using the immunohistochemical comprehensive scoring method,The receiver operating characteristic (ROC) curve was used to evaluate the value of PHOX2B immunohistochemistry comprehensive score in predicting neuroblastoma (NB), ganglionic neuroblastoma (GNB) mixed type (GNBi), ganglionic neuroblastoma nodular type (GNBn), and ganglionic neuroma (GN). 【Results】The number of cases of male and female patients was 33 and 32 respectively, with no significant gender difference; The age distribution was mainly among children under 6 years old, accounting for 75.38%(49/65); The retroperitoneum was a common primary site, followed by the mediastinum and adrenal gland. PHOX2B had the highest comprehensive immunohistochemical score in NB, followed by GNBn, with the weakest expression of GNBi and GN. The comprehensive immunohistochemical score in NB was significantly higher than that of GNBn, GNBi, and GN. The comprehensive immunohistochemical score of GNBn was significantly higher than that of GNBi and GN, and the differences were statistically significant (P<0.05). The ROC curve results showed that a PHOX2B immunohistochemical comprehensive score of 5 could be used as a reference threshold for diagnosing NB, and a PHOX2B immunohistochemical comprehensive score of 3 could be used as a reference threshold for diagnosing GNBn (P<0.05).【Conclusion】There are significant differences in the expression of PHOX2B among different types of pNTs, and its expression intensity can serve as a basis for pathological classification of pNTs.
TAN Zhiwen,CHEN Weijian,QIN Lei, et al. Differential Expression of PHOX2B in Four Subtypes of Peripheral Neuroblastoma Tissues[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 192-194.
[1] LUNDBERG K I, TREIS D, JOHNSEN J I. Neuroblastoma heterogeneity, plasticity, and emerging therapies[J].Current Oncology Reports,2022, 24(8): 1053-1062.
[2] ZEINELDIN M, PATEL A G, DYER M A. Neuroblastoma: When differentiation goes awry[J].Neuron,2022, 110(18): 2916-2928.
[3] 宋建明, 陈卫坚, 张文, 等. 外周神经母细胞性肿瘤病理诊断共识[J].中华病理学杂志, 2017, 46(7): 459-464.
[4] PEUCHMAUR M, D'AMORE E S, JOSHI V V, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular[J].Cancer,2003, 98(10): 2274-2281.
[5] PARK J R, KREISSMAN S G, LONDON W B, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: A randomized clinical trial[J].JAMA,2019, 322(8): 746-755.
[6] 陈卫坚, 周峥珍, 刘敏, 等. 神经母细胞瘤体表转移14例临床病理分析[J].中华小儿外科杂志,2015,35(1):17-20.
[7] 李静羽, 高吉照. 同源异型盒蛋白2B在外周神经母细胞性肿瘤中表达及临床意义[J].临床军医杂志, 2021, 49(1): 89.
[8] HUNG Y P, LEE J P, BELLIZZI A M, et al. PHOX2B reliably distinguishes neuroblastoma among small round blue cell tumours[J].Histopathology,2017, 71(5): 786-794.
[9] FAN H, XING T, HONG H, et al. The expression of PHOX2B in bone marrow and peripheral blood predicts adverse clinical outcome in non-high-risk neuroblastoma[J].Pediatric Hematol Oncol,2022, 39(4): 343-356.
[10] 禹乐, 陈淑敏, 王旭洲, 等. 两种不同BRAF抗体检测甲状腺微小乳头状癌BRAFV600E突变蛋白的免疫组化研究[J].临床肿瘤学杂志, 2020, 25(11): 988-992.
[11] PARK J R, BAGATELL R, COHN S L, et al. Revisions to the international neuroblastoma response criteria: A consensus statement from the national cancer institute clinical trials planning meeting[J].J Clin Oncol,2017, 35(22): 2580.
[12] CHOI J H, RO J Y. Mediastinal neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: Pathology review and diagnostic approach[J].Semin Diagn Pathol,2022, 39(2): 120.
[13] 许恪淳, 管雯斌, 许艳春, 等. 儿童神经母细胞源性肿瘤的形态及分子遗传学改变及临床意义[J].临床与实验病理学杂志, 2017, 33(7): 746-750.
2024, Vol. 41 
